Results 201 to 210 of about 1,916,955 (263)

A comparative mathematical modeling study of phenotypic approaches to T cell activation. [PDF]

Sci Rep
Bali Y, Rendall AD.
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

P16-18. Regulatory T cell frequencies correlate with T cell activation in chronic HIV-1 infection

Retrovirology, 2009
Walker BD, Altfeld M, Alter G, Pereyra F, Kwon D, Toth I, Trocha A, Pyo A, Wen F, Streeck H, Angin M, Addo MM   +11 more
doaj   +1 more source

Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy. [PDF]

J Immunother Cancer
Booth L, Adams R, Clifford A, Aguilar F, Ali N, Bishop C, Sufi J, Wu Y, Fitzpartick A, Geh JLC, MacKenzie Ross AD, Lloyd-Hughes H, Stodell M, Daniel CS, Whittaker S, Sinha K, Willsmore ZN, Terranova-Barberio M, Ali N, Lacy KE, Tull TJ, Tsoka S, Karagiannis SN.   +22 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function. [PDF]

Cell Death Dis
Onofrio LI, Abrate C, Strusberg I, Morales L, Ceschin DG, Montes CL, Stempin CC, Acosta Rodríguez E.   +7 more
europepmc   +1 more source

Arming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation. [PDF]

Mol Ther Oncol
Elsner L, Girod M, Hazini A, Geisler A, Heimann L, Dieringer B, Shipman-Mueller J, Thiel A, Klopfleisch R, Kurreck J, Van Linthout S, Fechner H.   +11 more
europepmc   +1 more source

Transcriptional and epigenetic control of human naïve CD8⁺ T cell activation. [PDF]

Front Immunol
Hu Y, Du Y, Chen X, Li Y, Yang C.
europepmc   +1 more source

Spatial transcriptomics maps early B-cell and T-cell activation in hidradenitis suppurativa. [PDF]

J Invest Dermatol
Lee J, Ham S, Lee J, Krueger JG, Lee YI, Kim J.   +5 more
europepmc   +1 more source

RMAD1, a Novel Cell-Penetrating Peptide Derived from ADARB2: Preclinical Insights into Antigen Uptake and T Cell Activation. [PDF]

Int J Biol Sci
Lim C, Park C, Song EC, Shin Y, Kim WK, Park YJ, Youn H, Ham C, Kim SB, Cho S.   +9 more
europepmc   +1 more source